Development of novel drug for drug-induced myocarditis using medical big data and omics data

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K20720
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0801:Pharmaceutical sciences and related fields
• Research Institution: The University of Tokushima
• Principal Investigator: NIIMURA Takahiro 徳島大学, 病院, 特任助教 (50910014)
• Project Period (FY): 2021-08-30 – 2023-03-31
• Keywords: 心筋炎 / 医療ビッグデータ

Outline of Final Research Achievements

By analyzing gene expression data in myocardial samples from mouse models of ICI-associated myocarditis, we identified several genes which expression was significantly altered in ICI-associated myocarditis. Based on the identified genes, we extracted several therapeutic candidates for ICI-related myocarditis by omics database analysis. Using mouse models of ICI-associated myocarditis, we found that the candidate drugs significantly attenuated inflammatory cell infiltration in the myocardium.

Free Research Field

医療系薬学

Academic Significance and Societal Importance of the Research Achievements

ICI関連心筋炎は、免疫チェックポイント阻害剤による致死的な有害事象のひとつで、発症後の致死率は50%にも上る。免疫チェックポイント阻害剤の適応がん種は、年々拡大しており、今後も免疫チェックポイント阻害剤の投与を受ける患者数は、増加することが予想される。ICI関連心筋炎に対する有効性の高い治療薬が開発されることで、安全な免疫療法の実現に寄与すると考えられる。